

# **Toxicity and biodistribution of surface chemically modified Ag nanoparticles**

Chengfang Pang<sup>1,2</sup>, Andrea Brunelli<sup>2</sup>, Danail Hristozov<sup>2</sup>, Elena Semenzin<sup>2</sup>, Antonio Marcomini<sup>2</sup>, Chunying Chen<sup>3</sup>, Bin Zhao<sup>1</sup>

<sup>1</sup>State Key Laboratory of Environmental Chemistry and Ecotoxicology, Chinese Academy of Sciences, China.

<sup>2</sup>Department of Environmental Sciences, Informatics and Statistics, University Ca' Foscari Venice, Italy.

<sup>3</sup>CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience and Technology of China, China.



Sustainable Nanotechnologies



SUN



**Textile** 

The total product amount of AgNPs Wound dressings reached up to 55 ton in 2012.



# **Risk of AgNPs?**



**Hazard:** AgNPs can migrate to liver, spleen, lungs, kidneys and brain and induce **toxicity** *in vivo* as well as induced apoptosis, membrane damage, inflammation and DNA damage *in vitro*.



# **Surface Modification**

With the advance in material science, AgNPs with **different surface coating** were exploited to develop faster electronic, brighter displays, and more sensitive diagnostic agents for medical imaging.



Figure: Relative size of nanoparticles and biomolecules, drawn to scale. Schematic representation of a nanoparticle with 5 nm core diameter, 10 nm shell diameter, with PEG molecules of 2000 and 5000 g mol-1 (on the left, light grey), streptavidin (green), transferrin (blue), antibody (lgG, purple), albumin (red), single-stranded DNA (20mer, cartoon and space filling). Proteins are crystal structures taken from the Protein Data Bank (http://www.rcsb.org) and displayed as surfaces; PEG and DNA have been modelled from their chemical structure and space filling. (Source from Sperling & Parak, 2010)



![](_page_5_Picture_0.jpeg)

# **Experimental Set Up**

![](_page_6_Figure_1.jpeg)

![](_page_7_Picture_0.jpeg)

# **Results and Discussion**

#### **Characterization of AgNPs in stock suspension**

Name	TEM Diameter (nm)(SD)	Hydrodyn amic Diameter (nm)	Zeta Potential (mv)	Mass Conc. (mg/ml)	Ag⁺ Conc. (µg/L)	
Citrate- AgNPs	28.7(3.6)	35.8	-22.9	1.14	0.43(0.10)	
PEG- AgNPs	32.9(3.2)	54.6	-16.2	1.08	0.45(0.03)	
PVP- AgNPs	28.7(2.1)	36.2	-22.1	1.07	0.58(0.10)	
BPEI- AgNPs	30.0(3.0)	63.0	46.5	0.49	0.80(0.07)	

![](_page_8_Picture_0.jpeg)

# **Results and Discussion**

### **TEM** image

![](_page_8_Figure_3.jpeg)

![](_page_9_Picture_0.jpeg)

Effects and uptake of AgNPs (Hepa1c1c7, 24h)

**Cell Viability** Uptake of AgNPs 140 A В Citrate AgNPs 6.00-PEG AgNPs # Intracelluber Silver (pg/cell) 120 PVP AaNPs BPEI AgNPs 5.00-Ag+ # # 100 \* ATP Content ( %) 4.00-80 3.00-60 2.00-40 1.00-20 0 0.00 10 0.1 25 50 5 **Control Citrate** PEG **PVP BPEI** Ag+ Concentration ( $\mu$ g/ml) AgNPs AgNPs AgNPs **AgNPs** 

> BPEI AgNPs treated cells showed the high toxicity to cells (p < 0.001).

- > PEG AgNPs treated cells showed the lowest toxicity (p < 0.05).
- The small amount AgNPs uptake by the cells showed the lower toxicity.

![](_page_10_Picture_0.jpeg)

#### **TEM-EDX** analysis of AgNPs in cells (Hepa1c1c7, 24h)

![](_page_10_Figure_3.jpeg)

![](_page_11_Picture_0.jpeg)

#### BPEI AgNPs entered into the nucleus (Hepa1c1c7, 24h)

![](_page_11_Picture_3.jpeg)

![](_page_12_Picture_0.jpeg)

#### **DNA fragmentation**

![](_page_12_Figure_3.jpeg)

**DNA** Content

> Only BPEI AgNPs treated cells showed DNA fragmentation (13.2%)

![](_page_13_Picture_0.jpeg)

### **Biodistribution**

Dose:1mg/kg mice (Balb/c, 24h exposure)

![](_page_13_Picture_4.jpeg)

![](_page_13_Figure_5.jpeg)

The silver levels were higher in spleen and liver followed in a decreasing order by lungs, gut, kidneys and brain after intravenous injection.

PEG AgNPs was highly uptaked by **spleen** of mice.  $\succ$ 

#### **Total Silver in Tissue**

![](_page_14_Picture_0.jpeg)

#### The evaluation of histopathological changes

	TEM Image of Liver	Liver	Spleen	Lung	Kidney	Liver	Spleen	Lung	Kidney
Control				J. A.	Ç)	_	-	_	_
Citrate AgNPs			1			+++	$\left  - \right\rangle$	+	++
PEG AgNPs						+	-	+	+
PVP AgNPs	N	E.				_	-	+	+++
BPEI AgNPs	N N N	0		SE		+	-	_	++
Ag+	N				<b>B</b>	_		_	++

![](_page_15_Picture_0.jpeg)

### **Results and Discussion in vivo** Pharmacokinetics of AgNPs in mice

![](_page_15_Figure_2.jpeg)

The elimination half-life of PEG AgNPs was much higher than other AgNPs and Ag+ treatments

	Time (n)					
Parameters		Two compartment model				
AgNPs	<b>Citrate AgNPs</b>	<b>PVP AgNPs</b>	<b>BPEI AgNPs</b>	$Ag^+$	PEG AgNPs	
AUC (h. $\mu g/g$ )	39.18	9.45	7.90	13.91	59.13	
$t_{1/2}^{\alpha}(h)$	0.11	0.02	0.05	0.10	51.65	
$t_{1/2}^{\ \beta}(h)$	17.81	3.03	6.76	15.79	—	
CL (g/h)	0.51	2.12	2.53	1.44	0.23	
CLD2(g/h)	10.14	37.90	30.72	19.20	—	
Vss (g)	12.66	8.86	23.24	30.87	14.18	
V1(g)	2.03	1.02	3.10	3.14	—	
V2 (g)	10.63	7.84	20.14	27.74		

![](_page_16_Picture_0.jpeg)

# Conclusions

Toxicity of AgNPs were surface chemistry dependent significantly: BPEI AgNPs > Citrate AgNPs = PVP AgNPs > PEG AgNPs

The surface charge played an important role: Positive surface charge (BPEI) AgNPs showed higher toxicity because of the strong interplay between the higher positive surface charge and the membrane of nucleus.

The PEG AgNPs showed higher bioaccumulation and low toxicity in spleen, and long half-life in blood indicated a high potential application in drug delivery.

![](_page_16_Picture_5.jpeg)

The toxicity of AgNPs in vitro was consistent with its in vivo which suggested an in vitro model using Hepa1c1c7 cell line connection with uncertainty factor in the risk assessment of AgNPs.

# Acknowledgements

National Science Foundation of China (Grant No.

21277168, 21321004, 21407162),

- The China Postdoctoral Science Foundation Project
  - (No. 2013M541056)
- The European Union Seventh Framework

Programme (Grant No. 604305, SUN).

We thank Molecular and Environmental Toxicology Group (RCEES, CAS) help for technical support.

![](_page_17_Picture_8.jpeg)

![](_page_17_Picture_9.jpeg)

![](_page_17_Picture_10.jpeg)

![](_page_17_Picture_11.jpeg)

![](_page_17_Picture_12.jpeg)

![](_page_18_Picture_0.jpeg)

# **Thank you for your attention!**

![](_page_19_Picture_0.jpeg)

### **Adsorption BSA ability of AgNPs**

Ag NPs (Citrate, PVP, PEG, BPEI)

BCA Protein Assay Kit Centrifugation BSA(Bovine Serum Albumin)

 $(C_0 - C_1)V$ 

q =

PEG AgNPs showed lower protein adsorption than other AgNPs particles (p < 0.05).</p>

The surface coating of PEG on AgNPs can diminish opsonization and therefore heavily reduced uptak of AgNPs into cells.

![](_page_19_Figure_7.jpeg)

![](_page_20_Picture_0.jpeg)

Bcl2

### **Results and Discussion in vitro**

#### Apoptosis: Gene expressions (Hepa1c1c7, 5µg/ml, 24h)

Caspase 3

![](_page_20_Figure_4.jpeg)

The expression of Caspase 3 gene in Ag+ treatment was significant upregulated (p < 0.05).</p>

> Bcl 2 gene expression showed significant low in Citrate AgNPs, PVP AgNPs, and BPEI AgNPs treatments than its in control (p < 0.05)

![](_page_21_Picture_0.jpeg)

![](_page_21_Figure_2.jpeg)

### Histopathology (AgNPs exposure 24h)

![](_page_22_Figure_2.jpeg)

![](_page_22_Picture_3.jpeg)

Dose:1mg/kg mice (Balb/c, 24 exposure)

Thickened alveolar walls and inflitration of focal inflammatory cells

![](_page_23_Figure_0.jpeg)

- Predicted

Time course of the mean blood silver levels (Observed) and the PBPK model values (Predicted) were obtained after a single injection of various AgNPs to mice. A. Citrated AgNPs; B. PEG AgNPs; C. PVP AgNPs; D. BPEI AgNPs; E. Ag+.

SUN